Press Release
Source: Viral Genetics, Inc.

Viral Genetics to Present at New York Society of Security Analysts 10th Annual Biotech and Specialty Pharmaceuticals Conference
AZUSA, Calif., Dec. 7, 2006

/PRNewswire-FirstCall/ -- Viral Genetics, Inc. (VRAL - news) will present at the NYSSA 10th Annual Biotech and Specialty Pharmaceutical Conference on December 12, 2006 at 2:20PM. The conference is taking place at the NYSSA offices in midtown New York.

About Viral Genetics
Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV and AIDS using its thymus nuclear protein compound. This compound may have other potential applications for other infectious, autoimmune, and immunological deficiency diseases that the company intends to study in the future. Viral Genetics believes that VGV-1 represents a significant and unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment. Online at www.viralgenetics.com.

About the New York Society of Security Analysts
Founded in 1937, NYSSA promotes awareness and understanding of securities analysis, investing, and the operation of the securities markets. With more than 9,000 members, NYSSA is the largest of the more than 134 financial analyst societies worldwide that comprise the CFA Institute.

For additional information, please contact Viral Genetics at 626-334-5310.

This news release contains forward-looking statements that involve risks and uncertainties associated with clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports filed with the SEC. VGV-1 is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of VGV-1 in the treatment of any disease or health condition and the development of studies and strategies leading to commercialization of VGV-1 in the United States. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.

CONTACT: Viral Genetics, +1-626-334-5310

Source: Viral Genetics, Inc.

Click here to return to our Press Release selection page.

Press Releases

Media Kits

Media Inquiries

News Subscription Service